Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1994-07-11
1996-01-02
Prescott, Arthur C.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C07D21340, A61K 3133, A61K 3134, A61K 31165
Patent
active
054808880
DESCRIPTION:
BRIEF SUMMARY
This application is a 371 of PCT/JP93100045 Jan. 14, 1993
TECHNICAL FIELD
The present invention relates to a pharmaceutical agent for inhibiting restenosis after percutaneous coronary arterioplasty (hereinafter referred to as PTCA).
BACKGROUND ART
PTCA is a relatively new approach to the treatment of ischemic heart diseases, which involves mechanical dilatation of the stenosed region of the coronary artery by balloons. However, the mechanically dilated part of the coronary arteries is known to undergo restenosis in several months after operation with a frequency of about 40%. Thus, PTCA is not a radical therapy for stenosed lesions of the coronary arteries. In order to inhibit the restenosis, antiplatelets, anticoagulants, etc. have heretofore been studied, but drugs which provide satisfactory clinical results have never been discovered.
Accordingly, there remains a need for a pharmaceutical agent which exhibits excellent inhibiting effect against restenosis after PTCA.
Compounds of the following formula (1) or (1') are known to be useful as antioxidants having glutathione peroxidase-like activity and/or lipoxigenase inhibitory activity (see, for example, Japanese Patent Application Laid-open Nos. 59-42373, 57-67568, 59-39894, 60-226868 and 61-50963, Biochemical Pharmacology, vol. 33, No. 20, 3235 to 3239 and 3241 to 3245 (1984)). However, the interrelation between these activities and the effect of inhibiting post-PTCA restenosis has remained unknown.
In view of the above, the inventors of the present invention have conducted careful studies and, as a result, have found that the compounds of the following formula (1) or (1') have an excellent effect of inhibiting restenosis after PTCA. The present invention has been accomplished based on this finding.
DISCLOSURE OF INVENTION
According to the present invention, there is provided an inhibitor for restenosis after percutaneous coronary arterioplasty, which comprises a compound of the following formula (1) or (1'), or a pharmaceutically acceptable salt thereof as an active ingredient: ##STR2## wherein R.sup.1 and R.sup.2 are independently a hydrogen atom, a halogen atom, a trifluoromethyl group, a nitro group, a C1-C6 alkyl group or a C1-C6 alkoxyl group, and R.sup.1 and R.sup.2 may be linked to form a methylenedioxy group; R.sup.3 is an optionally substituted aryl group, an optionally substituted aromatic heterocyclic group, an optionally substituted 5 to 7-membered cycloalkyl or cycloalkenyl group; R.sup.4 is a hydrogen atom, a hydroxyl group, an -S-glutathione residue, an -S-.alpha.-amino acid residue, or an aralkyl group optionally having substituent(s) in the aryl moiety; R.sup.5 is a hydrogen atom or a C1-C6 alkyl group, and R.sup.4 and R.sup.5 may be linked to form a single bond; Y is an oxygen atom or a sulfur atom; n is an integer of from 0 to 5, and the selenium atom may be oxidized.
Inhibitors for restenosis according to the present invention exhibit excellent effect of inhibiting restenosis after PTCA with low toxicity.
BEST MODE FOR CARRYING OUT THE INVENTION
The compounds which are used as active ingredients of inhibitors for restenosis after PTCA according to the present invention are represented by the above-mentioned formula (1) or (1') (hereinafter referred to as compound (1) or (1')). In the formulae, examples of C1-C6 alkyl groups of R.sup.1 include methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, sec-butyl and pentyl; examples of C1-C6 alkoxyl groups of R.sup.1 include methoxy, ethoxy and propoxy; examples of aryl groups of R.sup.3 include phenyl; examples of cycloalkyl groups of R.sup.3 include cyclopentyl, cyclohexyl and cycloheptyl; examples of cycloalkenyl groups of R.sup.3 include 1-cyclopentenyl, 1-cyclohexenyl and 1-cycloheptenyl; examples of aromatic heterocyclic groups include 5- or 6-membered aromatic heterocyclic groups such as pyridyl, pyrimidyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, furyl, etc. These groups may optionally have substituent(s). Examples of the substituents include a C1-C6 alkyl group, C1-
REFERENCES:
patent: 4711961 (1987-12-01), Welter et al.
patent: 5187105 (1993-02-01), Allbarella et al.
Hirayama Atsushi
Kodama Kazuhisa
Masayasu Hiroyuki
Daiichi Pharmaceutical Co. Ltd.
Prescott Arthur C.
LandOfFree
Inhibitor for restenosis after percutaneous coronary arterioplas does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Inhibitor for restenosis after percutaneous coronary arterioplas, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibitor for restenosis after percutaneous coronary arterioplas will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-235373